Hers weight loss review: what it really costs, and who it's for

Most women meet Hers the same way: a soft-lit ad, late at night, promising a doctor and a prescription without a single waiting room. Here is the reassuring part up front — for a lot of women, it delivers exactly that. Hers is a real telehealth service with licensed clinicians, and the process is genuinely fast and easy. The only thing worth slowing down for is understanding what you are actually signing up for, because the weight-loss line is broader than the ad lets on. This review walks through all of it.

What Hers is, in one minute

Hers is the women's side of Hims & Hers Health, a telehealth company large enough to be listed on the New York Stock Exchange. It has operated since 2017, prescribes through US-licensed clinicians in all fifty states, and fills through registered pharmacies. The weight-loss program is one of its biggest lines, and it does one thing very well: it removes nearly every obstacle between you and a supervised plan. You fill out a form, a clinician reviews it, and if you are a fit, medication ships to your door. For someone who has been brushed off by a busy doctor or who simply cannot fit another appointment into the week, that access is the whole point — and it is real.

The rest of this page is the detail underneath that promise: how the process works, every medication on the menu, what it truly costs once the membership is counted, the regulatory weather around the compounded versions, what customers report, and where it does and does not fit a body in perimenopause.

How Hers works, step by step

The flow is built to be frictionless, and it is. There is no video call required, which some women love and others wish were otherwise.

• You complete an online intake — health history, current medications, goals. It takes a few minutes, not an afternoon.
• A licensed clinician in your state reviews your answers and decides whether a weight-loss medication is appropriate and which one.
• If approved, you choose a plan, and the prescription is filled by a partner pharmacy and shipped to your door, usually within days.
• Your membership gives you ongoing clinician messaging, periodic check-ins, and nutrition guidance for the life of the plan.
• Refills arrive on a recurring schedule, and the subscription renews automatically until you cancel it.

That last line is the one to underline. Everything about Hers is designed to make starting effortless; the same machinery makes the recurring charge effortless too. Knowing that going in is most of what separates a happy customer from a frustrated one.

Every option on the menu

The single most useful thing to understand before you pay is that "Hers weight loss" is not one product. It branches, and the branches behave nothing alike. Here is each one, plainly.

The oral weight-loss kit (not a GLP-1)

The lowest-priced option is a kit of older oral medications — a clinician-chosen combination drawn from metformin, bupropion, and naltrexone. No needle, the smallest price, and a more modest effect than the injections everyone is talking about. It is worth saying clearly: this is not semaglutide, and it is not the drug in the ad that likely brought you here. For some women it is a sensible, affordable entry point, especially if they want to avoid injections. The trouble only starts when someone signs up expecting the GLP-1 and discovers later which product they actually bought.

Compounded semaglutide — injection and pill

This is the GLP-1 most people come for. Compounded semaglutide is the same active molecule as Wegovy, mixed by a compounding pharmacy rather than manufactured and approved as a finished drug. Hers offers it as a weekly injection and, since 2026, as a pill. The appeal is the price: it sits among the lowest GLP-1 starting points in the category, well under what brand-name costs without insurance. The asterisk — covered in its own section below — is that compounded medicine is not FDA-approved as a finished product.

Generic liraglutide

For women for whom semaglutide is not the right fit, Hers lists a generic liraglutide injection as a GLP-1 alternative. It is an older medication in the same family, typically priced a step above the compounded semaglutide injection. What Hers does not offer is compounded tirzepatide — so if a friend raved about that particular one, this is not where you will find it.

Brand-name Wegovy, Ozempic, and the rest

This is the newest and, for many women, the most important addition. After a turbulent year with Novo Nordisk, Hers now sells brand-name, FDA-approved GLP-1 medicines — Wegovy and Ozempic, in injection and pill form — at the same cash prices as other telehealth firms. That is a genuine shift from the compounded-only era and the better path for anyone who specifically wants the approved product rather than a compounded version. The catch is simply cost: brand-name cash prices are several times higher than the compounded route.

What it really costs

Hers advertises some of the lowest GLP-1 starting prices anywhere, and the sticker is genuinely low. Two things keep the real number honest, and neither is hidden so much as easy to miss.

First, the friendly monthly figure on the compounded injection generally assumes you pay upfront for a long plan — often six or twelve months at once. The low per-month price is real, but it is a sizeable single charge wearing a monthly costume, and refunds on an early exit are limited. Second, the membership is a separate line from the medication. The drug price and the platform fee are two charges, and the all-in monthly cost is the sum of them, not the headline alone.

Set against the brand-name cash prices, the gap is stark, and it is the whole reason the compounded route exists. The table above lays out each line so you can see which is which before you commit. Telehealth pricing also moves often and introductory rates expire, so treat every figure as a starting point to confirm at checkout.

Is it legit, and is the medication safe?

These are two different questions, and Hers answers them differently. As a company, it is plainly legitimate — the women's brand of an NYSE-listed firm, working through US-licensed clinicians and registered pharmacies, with real prescriptions and an A+ accreditation from the Better Business Bureau. Anyone calling it an outright scam is simply wrong.

The compounded medicine is where the asterisk lives, and it is fair to be matter-of-fact about it. Compounding is legal and long-standing, but a compounded drug is not FDA-approved as a finished product, which means it does not go through the agency review that vets a manufactured medicine for consistency. This is not abstract: in September 2025 the FDA sent Hers a warning letter over marketing language it said implied the compounded semaglutide was equivalent to the FDA-approved product. The broader fight with Novo Nordisk ran hot through the year — a brief partnership in spring 2025, an abrupt termination, a patent lawsuit in February 2026 — before the two sides reached a settlement in March 2026 under which Novo dropped the suit, Hers agreed to stop advertising compounded GLP-1 products, and brand-name Wegovy and Ozempic came onto the platform.

None of that makes the company a fraud, and the settlement actually widened your options. It does mean the compounded version carries regulatory weather the brand-name product does not — so the practical takeaway is simply to know which version you are being prescribed, and to choose it on purpose.

What customers actually report

Across thousands of reviews, the picture is genuinely mixed-to-positive, and the split is easy to read. The praise is consistent and centers on the same thing the brand promises: convenience. Sign-up takes minutes, a clinician responds quickly, the medication arrives, and plenty of women report real results and appreciate the bundled support. For a large share of customers, the experience matches the pitch.

The complaints are just as consistent, and they cluster — not on the medicine, but on the money, and specifically on the subscription. A big, responsive company can hold an A+ accreditation and still gather a tall stack of billing complaints, and that is roughly what you find here. The recurring themes are worth knowing so they never surprise you.

• Cancelling the medication does not cancel the membership — they are separate subscriptions, and people keep getting billed for the half they forgot.
• Charges can land for a renewed long plan, sometimes after a customer believed they had already cancelled.
• Prepaid multi-month plans are generally not refundable, which makes an early change of mind costly.
• Support can be slow to reach when a charge is the thing you are trying to stop.

The honest summary: the friction is almost never in getting in. It is in getting out cleanly. None of this is disqualifying — it is simply the thing to manage. Cancel both subscriptions, a few days before renewal, and keep the confirmations.

For the 40+ body: where Hers fits, and where it doesn't

Here is the question the ad never asks. The weight that arrived in your forties may not be a simple calorie story. As estrogen falls and fluctuates through perimenopause, fat redistributes toward the middle and insulin sensitivity drops, and the old rules quietly stop working. A general weight-loss subscription does not know any of that about you. The intake was not built to tell a thirty-year-old apart from a woman deep in the transition.

That is the real edge of Hers for a midlife body. A GLP-1 can absolutely help with the weight, and for many women it does. But Hers treats the weight as the whole problem, when for some women it is one symptom of a hormonal shift that medication alone will not address. There is no hormone therapy here and no menopause-literate adjustment to the plan. So the honest fit guidance is this: Hers suits a 40+ woman who wants fast, cash-pay convenience, knows which product she is choosing, and is comfortable managing the subscription deliberately. It is a weaker fit if you want insurance to carry the cost, the FDA-approved drug specifically, or a clinician keeping an eye on the wider hormonal picture rather than the scale alone.

How it compares, and the alternatives

Within the GLP-1 telehealth field, Hers competes mainly on price and ease, and it is strong on both. Where it is deliberately narrow is the menopause angle — it is a weight service, full stop. If that wider picture matters to you, the comparison worth making is not Hers against another weight app, but Hers against a menopause-literate provider who can look at hormones and weight together.

Bottom line: Hers earns its popularity. It is legitimate, fast, and among the cheapest doors into a supervised GLP-1 — a genuinely good fit for the right woman. Walk in knowing which of its products you want, that the membership is a separate charge, and how you will cancel, and it can do exactly what it promises.